Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

4 trials in Phase 3/4

Results Transparency

29%

2 of 7 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3

3(37.5%)

N/A

2(25.0%)

Phase 2

2(25.0%)

Phase 4

1(12.5%)

8Total

Phase 3(3)

N/A(2)

Phase 2(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT00266799Phase 3Completed

The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)

Role: collaborator

NCT00254982Phase 3Completed

Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)

Role: collaborator

NCT00941460Phase 2Completed

Comparison of Two Dosing Regimens of Temozolomide in Patients With Progressive or Recurrent Glioblastoma

Role: collaborator

NCT01384058Phase 4Completed

Effect of Ezetimibe or Simvastatin or Both on Low Densitiy Lipoprotein -Subfractions in Patients With Type 2 Diabetes

Role: collaborator

NCT00598611Phase 3Completed

Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU)

Role: collaborator

NCT00189410Phase 2Completed

Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours

Role: collaborator

NCT00963261Not ApplicableUnknown

Quality of Life and Psychological Well-being in Patients With Malignant Melanoma

Role: collaborator

NCT00805662Not ApplicableCompleted

Nasal Oxcytocin During IUI

Role: collaborator

All 8 trials loaded